Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
Tumor-Infiltrating lymphocyte grade IDs melanoma survival
Tumor-infiltrating lymphocyte grade is an independent predictor of melanoma-specific survival and sentinel lymph node status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

To investigate whether the density and distribution of TILs independently predicts SLN status and survival, Farhad Azimi, of the Melanoma Institute Australia in Sydney, and colleagues reviewed data from 1,865 patients with a single localized primary cutaneous melanoma ≥0.75 mm in thickness.

The researchers observed an inverse association between TIL grade and tumor thickness, mitotic rate, and Clark level. Sixty-one percent of patients underwent a SLN biopsy and 22.1 percent were positive. SLN positivity decreased with increasing TIL grade, ranging from 27.8 percent for TIL grade 0 to 5.6 percent for TIL grade 3 (P < 0.001). Decreasing age, decreasing TIL grade, ulceration, increasing tumor thickness, satellitosis, and increasing mitoses were significant predictors of SLN positivity. Independent predictors of melanoma-specific survival were tumor thickness, ulceration, satellitosis, mitotic rate, TIL grade, and sex. Survival was 100 percent in those with TIL grade 3.

"Ultimately, a greater understanding of the mechanisms controlling TILs in melanoma may provide avenues for developing important new immunotherapeutic strategies for patients with ," the authors write.

Explore further: Women have clear melanoma survival advantage over men

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Women have clear melanoma survival advantage over men

May 1, 2012
(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Ipilimumab active in advanced melanoma with brain mets

March 27, 2012
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.

Invasive melanoma may be more likely in children than adults

October 5, 2011
A Johns Hopkins Children's Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults.

Sentinel node biopsy safe, effective in head and neck melanomas

August 5, 2011
A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.